Premium
Clinical Experience with a New Solvent Detergent‐Treated Intravenous Immunoglobulin Free of Hypotensive Effects
Author(s) -
Chidwick K.,
Matejtschuk P.,
Gascoigne E.,
Briggs N.,
More J.E.,
Dash C.H.
Publication year - 1999
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1046/j.1423-0410.1999.7740204.x
Subject(s) - antibody , medicine , in vivo , clinical trial , immunoglobulin g , in vitro , immunology , anesthesia , pharmacology , chemistry , biology , biochemistry , microbiology and biotechnology
Objective:To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients. Methods: Clinical trials were done involving extensive patient monitoring during infusion: in vitro‐testing for markers of hypotension, and in vivo‐an animal model which closely simulates clinical use. Results: No hypotensive response was seen in the animal model or clinical trial. Conclusions: The production process used does not damage IgG or create vaso‐active kinins as the preparation was free of hypotensive effects.